8-Hydroxy-2′-deoxy-guanosine is a risk factor for development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection

Journal of Gastroenterology and Hepatology (Australia)

Volumn 23, Issue 9, 2008, Pages 1431-1436

  Chuma, Makoto ^a,b   Hige, Shuhei ^b   Nakanishi, Mitsuru ^b   Ogawa, Koji ^b   Natsuizaka, Mitsuteru ^b   Yamamoto, Yoichi ^b   Asaka, Masahiro ^b  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

Author keywords

8 hydroxy 2 deoxy guanosine (8 OHdG); Hepatitis C Virus; Hepatocellular carcinoma

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALANINE AMINOTRANSFERASE; REACTIVE OXYGEN METABOLITE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CANCER RISK; DIABETES MELLITUS; DNA DAMAGE; DRINKING BEHAVIOR; FATTY LIVER; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PATIENT MONITORING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TOBACCO;

EID: 49849091473     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2008.05502.x     Document Type: Article

References (34)

1. Kiyosawa K, Umemura T, Ichijo T et al. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 2004 127 : S17 26.
2. Lai MM. Hepatitis C virus proteins: direct link to hepatic oxidative stress, steatosis, carcinogenesis and more. Gastroenterology 2002 122 : 568 71.
3. Kasahara A, Hayashi N, Mochizuki K et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998 27 : 1394 402.
4. Makiyama A, Itoh Y, Kasahara A et al. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer 2004 101 : 1616 22.
5. Tokita H, Fukui H, Tanaka A et al. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy. J. Gastroenterol. Hepatol. 2005 20 : 752 8.
6. Marrero JA, Fontana RJ, Fu S, Conjeevaram HS, Su GL, Lok AS. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J. Hepatol. 2005 42 : 218 24.
7. El-Serag HB, Richardson PA, Everhart JE. The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans. Am. J. Gastroenterol. 2001 96 : 2462 7.
8. Fattovich G, Stroffolini T, Zagni I et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004 127 : S35 50.
9. Shibata M, Morizane T, Uchida T et al. Irregular regenera-tion of hepatocytes and risk of hepatocellular carcinoma in chronic hepatitis and cirrhosis with hepatitis-C-virus infec-tion. Lancet 1998 351 : 1773 7.
10. Bruno S, Stroffolini T, Colombo M et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007 45 : 579 87.
11. Tarao K, Rino Y, Ohkawa S et al. Close association between high serum alanine aminotransferase levels and multicentric hepatocarcinogenesis in patients with hepatitis C virus-associated cirrhosis. Cancer 2002 94 : 1787 95.
12. Yoshida H, Arakawa Y, Sata M et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002 123 : 483 91.
13. Shibutani S, Takeshita M, Grollman AP. Insertion of specific basesduring DNA synthesis past the oxidation-damaged base 8-oxdG. Nature 1991 349 : 431 4.
14. Kasai H. Analysis of a form of oxidative DNA damage 8-hydroxy-2- deoxyguanosine, as a marker of cellular oxidative stress during carci-nogenesis. Mutat. Res. 1997 387 : 147 63.
15. Chen X, Ding YW, Yang G, Bondoc F, Lee MJ, Yang CS. Oxidative damage in an esophageal adenocarcinoma model with rats. Carcinogenesis 2000 21 : 257 63.
16. Nakae D, Kobayashi Y, Akai H et al. Involvement of 8-hydroxyguanine formation in the initiation of rat liver carcinogenesis by low dose levels of N-nitrosodiethylamine. Cancer Res. 1997 57 : 1281 7.
17. Kitada T, Seki S, Iwai S, Yamada T, Sakaguti H, Wakasa K. In situ detection of oxidative DNA damage, 8-hydroxydeoxyguanosine, in chronic human liver disease. J. Hepatol. 2001 35 : 613 8.
18. Albadalejo J, Alonso R, Antinozzi R et al. Multicenter evaluation of the COBAS AMPLICOR HCV assay, an integrated PCR system for rapid detection of hepatitis C virus RNA in the diagnostic laboratory. J. Clin. Microbiol. 1998 36 : 862 5.
19. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997 20 : 1183 97.
20. Tsukiyama-Kohara K, Yamaguchi K, Maki N et al. Antigenicities of group 1 and 2 hepatitis C virus polypeptides: molecular basis of diagnosis. Virology 1993 192 : 430 7.
21. Simmonds P, Alberti A, Alter HJ et al. A proposed system for the nomenclature of hepatitis C virus genotypes. Hepatology 1994 19 : 1321 4.
22. Bruix J, Sherman M Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005 42 : 1208 36.
23. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 1999 94 : 2467 74.
24. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994 19 : 1513 20.
25. Altini M, Coleman H, Doglioni C, Favia G, Maiorano E. Calretinin expression in ameloblastomas. Histopathology 2000 37 : 27 32.
26. Schwarz KB, Kew M, Klein A et al. Increased hepatic oxidative DNA damage in patients with hepatocellular carcinoma. Dig. Dis. Sci. 2001 46 : 2173 8.
27. Horiike S, Kawanishi S, Kaito M et al. Accumulation of 8-nitroguanine in the liver of patients with chronic hepatitis C. J. Hepatol. 2005 43 : 403 10.
28. Cardin R, Saccoccio G, Masutti F, Bellentani S, Farinati F, Tiribelli C. DNA oxidative damage in leukocytes correlates with the severity of HCV-related liver disease: validation in an open population study. J. Hepatol. 2001 34 : 587 92.
29. Marotta F, Yoshida C, Barreto R, Naito Y, Packer L. Oxidative- inflammatory damage in cirrhosis: effect of vitamin E and a fermented papaya preparation. J. Gastroenterol. Hepatol. 2007 22 : 697 703.
30. Ichiba M, Maeta Y, Mukoyama T et al. Expression of 8-hydroxy-2′- deoxyguanosine in chronic liver disease and hepatocellular carcinoma. Liver Int. 2003 23 : 338 45.
31. Matsumoto K, Satoh Y, Sugo H et al. Immunohistochemical study of the relationship between 8-hydroxy-2′-deoxyguanosine levels in noncancerous region and postoperative recurrence of hepatocellular carcinoma in remnant liver. Hepatol. Res. 2003 25 : 435 41.
32. Sekoguchi S, Nakajima T, Moriguchi M et al. Role of cell-cycle turnover and oxidative stress in telomere shortening and cellular senescence in patients with chronic hepatitis C. J. Gastroenterol. Hepatol. 2007 22 : 182 90.
33. Kinoshita A, Wanibuchi H, Imaoka S et al. Formation of 8-hydroxydeoxyguanosine and cell-cycle arrest in the rat liver via generation of oxidative stress by phenobarbital: association with expression profiles of p21(WAF1/Cip1), cyclin D1 and Ogg1. Carcinogenesis 2002 23 : 341 9.
34. Shen J, Wanibuchi H, Salim EI et al. Liver tumorigenicity of trimethylarsine oxide in male Fischer 344 rats - association with oxidative DNA damage and enhanced cell proliferation. Carcinogenesis 2003 24 : 1827 35.